Check out our comprehensive educational activities here

In this setting of the COVID-19 pandemic, will clinical trials continue to enroll patients?

In this activity, Dr. Pollyea explains how the COVID-19 pandemic is impacting clinical trial enrollment in AML and MDS.

Published on April 8, 2020 in Treatment

What education instruction are you providing to your patients with AML who are already immunocompromised and are you continuing treatment as planned?

Join Dr. Pollyea as he discusses how to continue treatment with your patients who are already immunocompromised during the COVID-19 pandemic.

Published on April 8, 2020 in Treatment

How are you managing care delivery during the COVID-19 pandemic?

In this activity, Dr. Pollyea explains how the COVID-19 pandemic is impacting care delivery in his patients with AML.

Published on April 8, 2020 in Treatment

What are the advantages and disadvantages of the different FLT3 inhibitors?

There are several treatment options for AML that are FDA approved. In this activity, Dr. Perl discusses each FLT3 inhibitor and how it can be implemented into treatment.

Published on April 1, 2020 in Treatment

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory AML

Dr. Daver covers the results of the phase 1b study of venetoclax in combination with gilteritinib in patients with relapsed/refractory AML and what this approval could mean for future treatment.

Published on March 23, 2020 in Treatment

Challenges Associated with Relapse after Transplant in AML

Relapse is a devastating complication for patients with AML after transplant. In this activity, Dr. Giralt explains next steps.

Published on March 18, 2020 in Treatment

The Challenge of p53 Mutations in Treating AML

In this activity, Dr. Stein reviews the combination of APR-246 and azacitidine.

Published on March 16, 2020 in Treatment

COVID-19 Resources

MediCom Worldwide is committed to providing the most timely and relevant education to our membership, with the goal of improving patient care. In light of the COVID-19 pandemic, we are providing you with links to available resources on both general information about COVID-19 and the impact on patient care in the hematology/oncology setting. Please check these links periodically for any updates.

Published on March 16, 2020 in Treatment

Updates on the SIERRA Trial: An Investigation of Apamistamab-I-131

The SIERRA trial is a randomized phase 3 trial of an investigational radio-immune conjugate. In this activity, Dr. Giralt provides an update on the trial and what he hopes for in the future.

Published on March 9, 2020 in Treatment

Q-TWIST Analysis of Quizartinib vs. Salvage Chemotherapy in Patients with R/R FLT3-ITD AML

There has been much interest in developing new strategies for patients with FLT3-ITD mutated disease. In this activity, Dr. Cortes discusses the role of quizartinib in this setting.

Published on March 6, 2020 in Treatment